Here, we investigated the antimelanoma activity of combination therapy using NU7441 (NU) and the immune adjuvants STING ligand plus the CD40 antibody agonist (NU-SL40) in mice bearing immunoresistant B16-F10 melanoma tumors. The gene discussed is CD40; the disease is melanoma.